SMMT
Summit Therapeutics Inc. [SMMT] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SMMT Stock Summary
Top SMMT Correlated Resources
SMMT
Top 10 Correlated ETFs
SMMT
Top 10 Correlated Stocks
SMMT
In the News
SMMT Financial details
Company Rating
-
Market Cap
2.57B
Income
-1.65B
Revenue
235K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
105
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-1.31
Forward P/E
-
PEG
-0.01
P/S
9059.74
P/B
21.48
P/C
-
P/FCF
-41.67
Quick Ratio
1.76
Current Ratio
1.8
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-4.28
EPS next Y
-
EPS next Q
-
EPS this Y
160.53%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
39.12%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
70.82%
-
-
-
-
SMA20
22.73%
SMA50
12.5%
SMA100
42.11%
Inst Own
-
Inst Trans
-
ROA
-747%
ROE
-1363%
ROC
4.47%
Gross Margin
100%
Oper. Margin
198754%
Profit Margin
-692830%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.3-5.22
52W High
+440.49%
52W Low
+2602.44%
RSI
57
Rel Volume
0.22
Avg Volume
2.42M
Volume
534.27K
Perf Week
-3.52%
Perf Month
34.05%
Perf Quarter
34.38%
Perf Half Y
14.9%
-
-
-
-
Beta
-1.197
-
-
Volatility
0.67%, 2.69%
Prev Close
1.37%
Price
27.0244
Change
0.13%
Company Profile
- Volume Average 2.42M
- Market Capitalization 2.57B
- Employee 105
- CEO Mr. Robert W. Duggan
- Headquarters Cambridge,MA,US
- IPO Date 2015-03-05
-
Website
https://www.summittxinc.com 
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
